AU2004230244B2 - S. pneumoniae antigens - Google Patents

S. pneumoniae antigens Download PDF

Info

Publication number
AU2004230244B2
AU2004230244B2 AU2004230244A AU2004230244A AU2004230244B2 AU 2004230244 B2 AU2004230244 B2 AU 2004230244B2 AU 2004230244 A AU2004230244 A AU 2004230244A AU 2004230244 A AU2004230244 A AU 2004230244A AU 2004230244 B2 AU2004230244 B2 AU 2004230244B2
Authority
AU
Australia
Prior art keywords
seq
pneumoniae
antibody
nucleic acid
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004230244A
Other languages
English (en)
Other versions
AU2004230244A1 (en
Inventor
Shailesh Dewasthaly
Markus Hanner
Andreas Meinke
Eszter Nagy
Ulrike Stierschneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valneva Austria GmbH
Original Assignee
Intercell Austria AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercell Austria AG filed Critical Intercell Austria AG
Publication of AU2004230244A1 publication Critical patent/AU2004230244A1/en
Application granted granted Critical
Publication of AU2004230244B2 publication Critical patent/AU2004230244B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2004230244A 2003-04-15 2004-04-15 S. pneumoniae antigens Ceased AU2004230244B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03450087.6 2003-04-15
EP03450087 2003-04-15
PCT/EP2004/003984 WO2004092209A2 (en) 2003-04-15 2004-04-15 S. pneumoniae antigens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2011218655A Division AU2011218655A1 (en) 2003-04-15 2011-08-30 S. Pneumoniae Antigens

Publications (2)

Publication Number Publication Date
AU2004230244A1 AU2004230244A1 (en) 2004-10-28
AU2004230244B2 true AU2004230244B2 (en) 2011-09-22

Family

ID=33186037

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004230244A Ceased AU2004230244B2 (en) 2003-04-15 2004-04-15 S. pneumoniae antigens

Country Status (7)

Country Link
US (3) US7635487B2 (enExample)
EP (11) EP2336357A1 (enExample)
JP (3) JP2007525157A (enExample)
CN (2) CN1774447B (enExample)
AU (1) AU2004230244B2 (enExample)
CA (1) CA2522238A1 (enExample)
WO (1) WO2004092209A2 (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
US7128918B1 (en) 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
US7262024B2 (en) 2001-12-20 2007-08-28 Id Biomedical Corporation Streptococcus antigens
AU2004289295B2 (en) * 2003-11-10 2010-08-12 The Uab Research Foundation Compositions for reducing bacterial carriage and CNS invasion and methods of using same
JP5081243B2 (ja) * 2006-08-17 2012-11-28 ザ ユーエービー リサーチ ファウンデーション 肺炎球菌抗原を被検体における肺炎球菌性肺炎の指標とする方法
US8722055B2 (en) * 2006-09-27 2014-05-13 St. Jude Children's Research Hospital Synthetic Streptococcus pneumoniae vaccine
EP1923069A1 (en) * 2006-11-20 2008-05-21 Intercell AG Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
MX2009012676A (es) 2007-05-23 2010-02-12 Uab Research Foundation Neuraminidasa neumococica no toxica y sus usos.
BRPI0811908A2 (pt) * 2007-05-25 2014-11-18 Novartis Ag Antígenos de pilus de streptococcus pneumoniae
US20160228500A9 (en) * 2007-07-23 2016-08-11 Martina Ochs Immunogenic Polypeptides and Monoclonal Antibodies
CN101802198B (zh) * 2007-07-23 2016-02-17 圣诺菲·帕斯图尔有限公司 免疫原性多肽和单克隆抗体
GB0714963D0 (en) * 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
CN105044337A (zh) * 2008-02-01 2015-11-11 圣诺菲·帕斯图尔有限公司 用于诊断肺炎链球菌的试验
PT2268618E (pt) 2008-03-03 2015-10-12 Novartis Ag Compostos e composições moduladores da actividade tlr
AU2009226949A1 (en) 2008-03-17 2009-09-24 Intercell Ag Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
EP2108656A1 (en) * 2008-03-19 2009-10-14 Beninati, Concetta Antigenic protein fragments of streptococcus pneumoniae
US11839430B2 (en) 2008-03-27 2023-12-12 Doheny Eye Institute Optical coherence tomography-based ophthalmic testing methods, devices and systems
US8348429B2 (en) 2008-03-27 2013-01-08 Doheny Eye Institute Optical coherence tomography device, method, and system
US20110171224A1 (en) * 2008-05-22 2011-07-14 Orihuela Carlos J PsrP IS A PROTECTIVE ANTIGEN AGAINST PNEUMOCOCCAL INFECTION
WO2010009450A1 (en) 2008-07-18 2010-01-21 Doheny Eye Institute Optical coherence tomography device, method, and system
ES2352704B1 (es) * 2008-08-08 2012-06-14 CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC)(Titular al 80%) Secuencia de nucleotido y proteina b-galactosidasa de streptococcus mitis, procedimiento de obtencion y sus aplicaciones.
EP2327782B1 (en) * 2008-09-04 2015-02-25 Biotechnology Research Institute Chinese Academy of Agricultural Sciences Dna molecule for expressing haripin rna, the constructing method and the use thereof
WO2010029546A2 (en) * 2008-09-11 2010-03-18 Ben Gurion University Of The Negev Research And Development Authority Compositions and methods for treating s.pneumoniae infection
EP2218457B1 (en) * 2009-02-16 2011-09-07 Karlsruher Institut für Technologie CD44v6 peptides as inhibitors of bacterial infections
NZ595291A (en) 2009-03-24 2013-08-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
AU2010258677B2 (en) 2009-06-10 2016-10-06 Glaxosmithkline Biologicals S.A. Benzonaphthyridine-containing vaccines
SG10201403702SA (en) * 2009-06-29 2014-09-26 Genocea Biosciences Inc Vaccines and compositions against streptococcus pneumoniae
JP5988492B2 (ja) 2009-09-02 2016-09-07 ノバルティス アーゲー Ｔｌｒ活性モジュレーターを含む免疫原性組成物
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
WO2011030218A1 (en) 2009-09-10 2011-03-17 Novartis Ag Combination vaccines against respiratory tract diseases
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
WO2011084549A1 (en) 2009-12-15 2011-07-14 Novartis Ag Homogeneous suspension of immunopotentiating compounds and uses thereof
JP2013525271A (ja) * 2010-03-12 2013-06-20 チルドレンズ メディカル センター コーポレーション 免疫原およびそのスクリーニング方法
EA031379B1 (ru) 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
JP6046632B2 (ja) 2010-12-03 2016-12-21 サノフィ パストゥール リミテッドＳａｎｏｆｉ Ｐａｓｔｅｕｒ Ｌｉｍｉｔｅｄ 肺炎球菌に対する免疫用組成物
MY163871A (en) * 2011-01-20 2017-10-31 Genocea Biosciences Inc Vaccines and compositions against streptococcus pneumoniae
ES2864764T3 (es) 2011-05-11 2021-10-14 Childrens Medical Center Composición inmunogénica que presenta múltiples antígenos, y métodos y usos de la misma
AU2012335208B2 (en) 2011-11-07 2017-08-31 Glaxosmithkline Biologicals S.A. Carrier molecule comprising a spr0096 and a spr2021 antigen
AU2013224026A1 (en) * 2012-02-24 2014-08-21 Novartis Ag Pilus proteins and compositions
CN104519910B (zh) 2012-03-07 2017-05-03 诺华股份有限公司 肺炎链球菌抗原的含佐剂制剂
ES2820898T3 (es) 2012-05-22 2021-04-22 Glaxosmithkline Biologicals Sa Conjugado del serogrupo X de meningococos
RU2510281C2 (ru) 2012-06-22 2014-03-27 Общество с ограниченной ответственностью "Эпитоп" (ООО "Эпитоп") ВАКЦИНА ПРОТИВ ПНЕВМОНИИ, ВЫЗЫВАЕМОЙ Streptococcus pneumoniae, НА ОСНОВЕ ГИБРИДНОГО БЕЛКА
WO2014018904A1 (en) * 2012-07-26 2014-01-30 Genocea Biosciences, Inc. Fused antigen vaccines and compositions against streptococcus pneumoniae
ES2670863T3 (es) 2013-02-01 2018-06-01 Glaxosmithkline Biologicals Sa Administración intradérmica de composiciones inmunológicas que comprenden agonistas del receptor de tipo Toll
EP4272750A3 (en) 2013-02-07 2024-01-24 Children's Medical Center, Corp. Protein antigens that provide protection against pneumococcal colonization and/or disease
US9226856B2 (en) 2013-03-14 2016-01-05 Envision Diagnostics, Inc. Inflatable medical interfaces and other medical devices, systems, and methods
US10772497B2 (en) 2014-09-12 2020-09-15 Envision Diagnostics, Inc. Medical interfaces and other medical devices, systems, and methods for performing eye exams
CN108138216A (zh) * 2015-06-18 2018-06-08 般财团法人阪大微生物病研究会 肺炎球菌补体依赖性杀菌能力测量方法
EP3834705B1 (en) 2015-09-17 2023-12-20 Envision Diagnostics, Inc. Medical interfaces and other medical devices, systems, and methods for performing eye exams
WO2017190087A1 (en) 2016-04-30 2017-11-02 Envision Diagnostics, Inc. Medical devices, systems, and methods for performing eye exams and eye tracking
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
US20200038499A1 (en) * 2017-03-22 2020-02-06 Modernatx, Inc. Rna bacterial vaccines
US11305001B2 (en) 2017-03-28 2022-04-19 The Children's Medical Center Corporation Multiple antigen presenting system (MAPS)-based Staphylococcus aureus vaccine, immunogenic composition, and uses thereof
CN111065417B (zh) 2017-06-23 2024-04-19 美商艾芬尼维克斯公司 免疫原性组合物
US11458151B2 (en) 2018-02-12 2022-10-04 Inimmune Corporation Toll-like receptor ligands
GB201807380D0 (en) 2018-05-04 2018-06-20 Karlsson Roger Biomarkers for detecting microbial infection
SG11202101973YA (en) 2018-09-12 2021-03-30 Childrens Medical Ct Corp Pneumococcal fusion protein vaccines
PE20211112A1 (es) 2018-09-12 2021-06-22 Affinivax Inc Vacunas neumococicas multivalentes
RU2701733C1 (ru) * 2018-12-14 2019-10-01 Федеральное государственное бюджетное научное учреждение "Институт экспериментальной медицины" (ФГБНУ "ИЭМ") Живая вакцина на основе штамма пробиотиков ENTEROCOCCUS FAECIUM L3 для профилактики инфекции, вызванной STREPTOCOCCUS PNEUMONIE
CN111748535B (zh) * 2019-03-28 2022-07-05 安徽华恒生物科技股份有限公司 一种丙氨酸脱氢酶突变体及其在发酵生产l-丙氨酸中的应用
JP2023547677A (ja) 2020-11-04 2023-11-13 エリゴ・バイオサイエンス キューティバクテリウム・アクネス組換えファージ、その産生方法及び使用
GB202100097D0 (en) * 2021-01-05 2021-02-17 Univ Liverpool Novel composition
WO2023039223A1 (en) 2021-09-09 2023-03-16 Affinivax, Inc. Multivalent pneumococcal vaccines
JP2025523396A (ja) * 2022-06-07 2025-07-23 ペキン ユニバーシティ ファースト ホスピタル ＩｇＡプロテアーゼトランケートを含む融合タンパク質及びその用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049721A2 (en) * 1999-12-30 2001-07-12 Bristol-Myers Squibb Company Bacterial genes and proteins that are essential for cell viability and their uses
WO2002077021A2 (en) * 2001-03-27 2002-10-03 Chiron Srl. Streptococcus pneumoniae proteins and nucleic acids

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US40000A (en) 1863-09-15 Improvement in sewing-machines
US4609231A (en) 1984-12-24 1986-09-02 Perfectdata Corporation Floppy diskette storage container
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP1695978A1 (en) 1990-06-11 2006-08-30 Gilead Sciences, Inc. Nucleic acid ligands
DE10075010I2 (de) 1990-06-28 2004-01-29 Hoechst Ag Fusionsproteine mit immunglobulinanteilen, ihre Herstellung und Verwendung.
ATE229543T1 (de) 1991-06-24 2002-12-15 Chiron Corp Polypeptide des hepatitis c-virus (hiv)
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
CA2224015A1 (en) * 1995-06-07 1996-12-19 Biochem Vaccines Inc. Streptococcal heat shock proteins members of the hsp70 family
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
DE59708838D1 (de) 1996-08-30 2003-01-09 Jens Peter Fuerste Spiegelselektion und spiegelevolution von nucleinsäuren
US5989912A (en) 1996-11-21 1999-11-23 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
EP0942983B2 (en) * 1996-10-31 2014-09-10 Human Genome Sciences, Inc. Streptococcus pneumoniae antigens and vaccines
WO1998019689A1 (en) * 1996-11-01 1998-05-14 Smithkline Beecham Corporation Novel coding sequences
US6271000B1 (en) * 1996-12-13 2001-08-07 Eli Lilly And Company Streptococcus pneumoniae gene sequence mraY
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
DE19803453A1 (de) 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
ATE361365T1 (de) * 1998-07-27 2007-05-15 Sanofi Pasteur Ltd Streptococcus pneumoniae proteine und nukleinsäuren
WO2000006738A2 (en) * 1998-07-27 2000-02-10 Microbial Technics Limited NUCLEIC ACIDS AND PROTEINS FROM $i(STREPTOCOCCUS PNEUMONIAE)
US6951652B2 (en) * 1998-07-29 2005-10-04 Biosynth S.R.L. Vaccine for prevention of gram-negative bacterial infections and endotoxin related diseases
AU2027400A (en) * 1998-11-19 2000-06-05 St. Jude Children's Research Hospital Identification and characterization of novel pneumococcal choline binding proteins, cbpg and cbpd, and diagnostic and therapeutic uses thereof
PT2261358E (pt) * 1998-12-23 2014-07-30 Id Biomedical Corp Quebec Antigénios de streptococcus
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
ATE375169T1 (de) 2000-04-14 2007-10-15 Intercell Ag Modifizierte peptide enthaltende pharmazeutische präparationen
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
HU228264B1 (en) 2000-06-08 2013-02-28 Intercell Ag Immunostimulatory oligodeoxynucleotides
AU2000279060A1 (en) 2000-07-10 2002-01-21 Telefonaktiebolaget Lm Ericsson (Publ) Resource management in uncoordinated frequency hopping system
CA2418854A1 (en) 2000-08-17 2002-02-21 Jorg Fritz A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
IL154853A0 (en) 2000-10-27 2003-10-31 Chiron Spa Nucleic acids and proteins from streptococcus groups a & b
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
US7482012B2 (en) 2001-02-21 2009-01-27 Id Biomedical Corporation Streptococcus pyogenes polypeptides and corresponding DNA fragments
WO2002077183A2 (en) * 2001-03-21 2002-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
CA2443493A1 (en) 2001-04-13 2002-10-24 Wyeth Surface proteins of streptococcus pyogenes
CA2444133A1 (en) * 2001-04-16 2002-10-24 Wyeth Holdings Corporation Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
FR2824074A1 (fr) 2001-04-26 2002-10-31 Pasteur Institut Sequence du genome streptococcus agalactiae, application au developpement de vaccins, d'outils de diagnostic, et a l'identification de cibles therapeutiques
AU2002358616A1 (en) 2001-12-07 2003-06-17 Intercell Ag Immunostimulatory oligodeoxynucleotides
GB0210128D0 (en) 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
WO2005032582A2 (en) 2003-07-31 2005-04-14 Chiron Corporation Immunogenic compositions for streptococcus pyogenes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049721A2 (en) * 1999-12-30 2001-07-12 Bristol-Myers Squibb Company Bacterial genes and proteins that are essential for cell viability and their uses
WO2002077021A2 (en) * 2001-03-27 2002-10-03 Chiron Srl. Streptococcus pneumoniae proteins and nucleic acids

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BETHE, G. et al., FEMS Microbiology Letters, 2001, vol. 205, pages 99-104 *
HOSKINS, J. et al., Journal of Bacteriology, 2001, vol. 183, pages 5709-5717 *
NABORS, G.S. et al., Vaccine, 2000, vol. 18, pages 1743-1754 *
OVERWEG, K. et al., Infection and Immunity, 2000, vol. 68, pages 4180-4188 *
TETTELIN, H. et al., Science, 2001, vol. 293, pages 498-506 *
WIZEMANN, T.M. et al., Infection and Immunity, 2001, vol. 69, pages 1593-1598 *

Also Published As

Publication number Publication date
US20060263846A1 (en) 2006-11-23
AU2004230244A1 (en) 2004-10-28
US20130136761A1 (en) 2013-05-30
CN102174534A (zh) 2011-09-07
EP1615950A2 (en) 2006-01-18
EP2314719A1 (en) 2011-04-27
EP2336357A1 (en) 2011-06-22
EP2311988A1 (en) 2011-04-20
JP2012184236A (ja) 2012-09-27
CN1774447B (zh) 2011-04-06
EP2333114A1 (en) 2011-06-15
WO2004092209A9 (en) 2008-11-27
EP2311990A1 (en) 2011-04-20
CN1774447A (zh) 2006-05-17
EP2314718A1 (en) 2011-04-27
CA2522238A1 (en) 2004-10-28
EP2311989A1 (en) 2011-04-20
US7635487B2 (en) 2009-12-22
WO2004092209A3 (en) 2004-12-09
JP2011004753A (ja) 2011-01-13
US8372411B2 (en) 2013-02-12
US20100260790A1 (en) 2010-10-14
WO2004092209A2 (en) 2004-10-28
EP2298934A1 (en) 2011-03-23
HK1084958A1 (en) 2006-08-11
EP2311987A1 (en) 2011-04-20
JP2007525157A (ja) 2007-09-06
EP2311991A1 (en) 2011-04-20

Similar Documents

Publication Publication Date Title
AU2004230244B2 (en) S. pneumoniae antigens
CA2413450C (en) Streptococcus antigens
US8431128B2 (en) Enterococcus antigens
JPH11513371A (ja) 肺炎球菌遺伝子、その一部、それ由来の発現産物、ならびに該遺伝子、該遺伝子の一部分、および該遺伝子産物の使用
IL137921A (en) Proteins and polypeptides of group B streptococcus
US20040096973A1 (en) Environmentally regulated genes of Streptococcus suis
US6764823B2 (en) Antimicrobial methods and materials
AU2011218655A1 (en) S. Pneumoniae Antigens
US20100221277A1 (en) Chlamydia pneumoniae antigens
HK1084958B (en) S. pneumoniae antigens
AU2011236092A1 (en) Enterococcus Antigens

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired